Mid Atlantic Bio Angels

About Mid Atlantic Bio Angels

This author has not yet filled in any details.
So far Mid Atlantic Bio Angels has created 27 blog entries.

Is Angel Capital or Venture Capital Right for Your Company?

MABA is regularly approached by companies seeking funds for their life sciences startups (therapeutics, devices, diagnostics and digital health). One of the first things we discuss is their total funding needs to reach an exit, and the difference between angel and venture capital (VC). Understanding the difference can help you set the best strategy for your company. Once you have reached the stage where it is time to raise funds, some companies are better suited for, or would prefer angel funding, while others are more appropriate for venture capital. 

There are many differences between angel investors and VCs, including the source [ Read more… ]

2022-12-07T13:56:04+00:00December 7th, 2022|

Is now the best time to be an angel investor?

“And just like that, he’s gone”

For fans of the movie The Usual Suspects, that line captured what it was like to wake up to the investment reality of 2022.

2020 and 2021 were banner years for companies going public any way they could, including SPACs, which skyrocketed in popularity in 2020 but had fallen back to earth by the end of last year.  These exits provided returns to their investors, which resulted in more and new investors who went on to raise new and larger funds.

And now all this new money was looking for more and more investment opportunities, to which [ Read more… ]

2022-09-15T12:38:16+00:00June 2nd, 2022|

Restricted

Posted: December 24, 2021

Dear Sidecar Fund Investors,

We hope that everyone remains healthy and is doing well.

As we near the Fund’s second anniversary, the Fund has made six investments so far, several were in companies that were new to us, and several were in existing MABA portfolio companies, and there is room left for just one more large investment, before the Fund is fully invested.

The pandemic has affected a significant drop in applications in the first half of 2021, with numbers recovering somewhat, beginning in September.  This resulted in a much smaller than usual amount of companies entering diligence, with, [ Read more… ]

2022-09-15T13:06:49+00:00December 24th, 2021|

Restricted

Posted June 11, 2021

Dear Sidecar Fund I investors,

We hope that everyone is healthy (and vaccinated) and doing well.

Our portfolio companies continue to execute on their plans and their regular reports are being updated to this site, as they are received.  I hope you are as happy to read of some of the progress being reported as we are. Also, I recently reached out to all of our portfolio company CEOs for an in-person update on their activities, which you can read in the attached Dashboard.

The general market is beginning to see a rebound, as Covid-19 cases decline, and restrictions [ Read more… ]

2022-09-15T13:07:48+00:00June 11th, 2021|

Restricted

Posted December 22, 2020

We hope everyone is staying healthy and safe.

We are happy to announce that the Sidecar Fund has made an investment in Seneca Therapeutics, “developing a pipeline of best-in-class oncolytic immunotherapeutics that are highly effective in treating cancer patients with solid cancers.” They are trying to “convert the tumor microenvironment from cold to hot”, or, in other words, convert undruggable cancer targets into druggable candidates. They are led by an industry-experienced CEO, who recently joined the team.

Although the pandemic is currently seeing a significant surge in numbers, the recent release of the Pfizer and Moderna vaccines provide [ Read more… ]

2022-09-15T13:08:29+00:00December 2nd, 2020|

Restricted

Summary

Novel neuroprotective therapeutics for the treatment of stroke, traumatic brain injury (TBI), concussion, and neurodegenerative diseases.

Documents

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Astrocyte Pharmaceuticals 2022 Q2 Investor Update

Astrocyte Pharmaceuticals 2022 Q1 Investor Update

Astrocyte Pharmaceuticals 2021 Q4 Investor Update

Astrocyte awarded major grant for brain injury Astrocyte Pharmaceuticals 2021 Q2 Investor Update

Astrocyte Investor Welcome

Astrocyte Pharmaceuticals 2021 [ Read more… ]

2023-01-26T14:13:53+00:00November 23rd, 2020|
Go to Top